PURPOSE: The Pre-familial Amyotrophic Lateral Sclerosis (Pre-fALS) study is a longitudinal study of individuals potentially at risk for developing familial amyotrophic lateral sclerosis. Our goals were to (1) explore participants' decisions of whether to learn results of presymptomatic testing or not; (2) understand the psychosocial impact of these decisions; and (3) assess preferences for receiving results by telephone or in person. METHODS: The sample for this substudy comprised 20 participants drawn randomly from autosomal dominant mutant superoxide dismutase 1 families in the Pre-fALS study. Twenty participants completed a semistructured phone interview; prominent themes were identified and rated. RESULTS: Fourteen participants chose to learn results; six had mutant superoxide dismutase 1 and eight had wild-type superoxide dismutase 1. Of the six who initially elected nondisclosure, three were reconsidering their decision. Regardless of the results and method of counseling, participants had adapted well, at least in the short term. CONCLUSION: We recommend that (1) those considering presymptomatic genetic testing should undergo professional counseling to help decide whether to learn results; (2) discussion should include the option of telephone genetic counseling for those without easy access to in-person counseling; and (3) those who initially decline to learn results should be offered the opportunity to learn their mutation status as their decision evolves.
PURPOSE: The Pre-familial Amyotrophic Lateral Sclerosis (Pre-fALS) study is a longitudinal study of individuals potentially at risk for developing familial amyotrophic lateral sclerosis. Our goals were to (1) explore participants' decisions of whether to learn results of presymptomatic testing or not; (2) understand the psychosocial impact of these decisions; and (3) assess preferences for receiving results by telephone or in person. METHODS: The sample for this substudy comprised 20 participants drawn randomly from autosomal dominant mutant superoxide dismutase 1 families in the Pre-fALS study. Twenty participants completed a semistructured phone interview; prominent themes were identified and rated. RESULTS: Fourteen participants chose to learn results; six had mutant superoxide dismutase 1 and eight had wild-type superoxide dismutase 1. Of the six who initially elected nondisclosure, three were reconsidering their decision. Regardless of the results and method of counseling, participants had adapted well, at least in the short term. CONCLUSION: We recommend that (1) those considering presymptomatic genetic testing should undergo professional counseling to help decide whether to learn results; (2) discussion should include the option of telephone genetic counseling for those without easy access to in-person counseling; and (3) those who initially decline to learn results should be offered the opportunity to learn their mutation status as their decision evolves.
Authors: Matthew J Greenway; Peter M Andersen; Carsten Russ; Sean Ennis; Susan Cashman; Colette Donaghy; Victor Patterson; Robert Swingler; Dairin Kieran; Jochen Prehn; Karen E Morrison; Andrew Green; K Ravi Acharya; Robert H Brown; Orla Hardiman Journal: Nat Genet Date: 2006-02-26 Impact factor: 38.330
Authors: Kimberly A Quaid; Sharon L Sims; Melinda M Swenson; Joan M Harrison; Carol Moskowitz; Nonna Stepanov; Gregory W Suter; Beryl J Westphal Journal: J Genet Couns Date: 2007-10-18 Impact factor: 2.537
Authors: Vivianna M Van Deerlin; James B Leverenz; Lynn M Bekris; Thomas D Bird; Wuxing Yuan; Lauren B Elman; Dana Clay; Elisabeth McCarty Wood; Alice S Chen-Plotkin; Maria Martinez-Lage; Ellen Steinbart; Leo McCluskey; Murray Grossman; Manuela Neumann; I-Lin Wu; Wei-Shiung Yang; Robert Kalb; Douglas R Galasko; Thomas J Montine; John Q Trojanowski; Virginia M-Y Lee; Gerard D Schellenberg; Chang-En Yu Journal: Lancet Neurol Date: 2008-04-07 Impact factor: 44.182
Authors: A Chiò; B J Traynor; F Lombardo; M Fimognari; A Calvo; P Ghiglione; R Mutani; G Restagno Journal: Neurology Date: 2008-02-12 Impact factor: 9.910
Authors: Samantha Galluzzi; Anna Mega; Giuseppe Di Fede; Cristina Muscio; Sara Fascendini; Luisa Benussi; Fabrizio Tagliavini; Giovanni B Frisoni; Emilio Di Maria Journal: Alzheimer Dis Assoc Disord Date: 2022-03-16 Impact factor: 2.357
Authors: Michael Benatar; Joanne Wuu; Caroline McHutchison; Ronald B Postuma; Bradley F Boeve; Ronald Petersen; Christopher A Ross; Howard Rosen; Jalayne J Arias; Stephanie Fradette; Michael P McDermott; Jeremy Shefner; Christine Stanislaw; Sharon Abrahams; Stephanie Cosentino; Peter M Andersen; Richard S Finkel; Volkan Granit; Anne-Laure Grignon; Jonathan D Rohrer; Corey T McMillan; Murray Grossman; Ammar Al-Chalabi; Martin R Turner Journal: Brain Date: 2022-03-29 Impact factor: 15.255
Authors: Marian Reiff; Barbara A Bernhardt; Surabhi Mulchandani; Danielle Soucier; Diana Cornell; Reed E Pyeritz; Nancy B Spinner Journal: Genet Med Date: 2012-01-05 Impact factor: 8.822